Ra Pharmaceuticals Inc (RARX.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|President, Chief Executive Officer, Co-Founder, Director|
|Senior Vice President, Chief Medical Officer|
|Senior Vice President of Research & Development|
|Executive Director, Operations|
- BRIEF-Ra Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of RA101495 SC
- BRIEF-Ra Pharmaceuticals posts Q3 loss of $0.68 per share
- BRIEF-Ra Pharmaceuticals files for mixed shelf offering of up to $250 million
- BRIEF-Ra Pharmaceuticals reports Q2 loss per share $0.56
- BRIEF-RA Pharmaceuticals receives orphan drug designation from FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria